TC
CGON icon

TwinBeech Capital’s CG Oncology CGON Stock Holding History

TwinBeech Capital’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,100
Closed -$461K – 602
2025
Q4 		$461K Buy
+11,100
New +$459K 0.03% 411
2025
Q3 		– Sell
-26,979
Closed -$701K – 597
2025
Q2 		$701K Buy
+26,979
New +$650K 0.02% 458

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TwinBeech Capital's CGON Position: Q1 2026 in Review

TwinBeech Capital sold out of CG Oncology (CGON) in Q1 2026, closing a stake of 11,100 shares — an estimated $461K sold.

TwinBeech Capital first reported a position in CGON in Q2 2025 and held it in 2 quarters. The position peaked at $701K in Q2 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • TwinBeech Capital reported no remaining CG Oncology position as of Q1 2026 after selling out during the quarter.
  • TwinBeech Capital sold 11,100 CG Oncology shares in Q1 2026, an estimated $461K.
  • TwinBeech Capital first reported a position in CG Oncology in Q2 2025 and held it in 2 quarters.
  • TwinBeech Capital's CG Oncology position peaked at $701K in Q2 2025.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on TwinBeech Capital's 13F filing for Q1 2026, filed 15 May 2026.